liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Second-look resection for primary stage T1 bladder cancer: a population-based study
Lund University, Sweden; Skåne University Hospital, Sweden.
Sahlgrens University Hospital, Sweden.
Karolinska University Hospital, Sweden.
Lund University, Sweden; Skåne University Hospital, Sweden.
Vise andre og tillknytning
2017 (engelsk)Inngår i: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 51, nr 4, s. 301-307Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: This study aimed to evaluate the use of second-look resection (SLR) in stage T1 bladder cancer (BC) in a population-based Swedish cohort. Materials and methods: All patients diagnosed with stage T1 BC in 2008-2009 were identified in the Swedish National Registry for Urinary Bladder Cancer. Registry data on TNM stage, grade, primary treatment and pathological reports from the SLR performed within 8weeks of the primary transurethral resection were validated against patient charts. The endpoint was cancer-specific survival (CSS). Results: In total, 903 patients with a mean age of 74years (range 28-99 years) were included. SLR was performed in 501 patients (55%), who had the following stages at SLR: 172 (35%) T0, 83 (17%) Ta/Tis, 210 (43%) T1 and 26 (5%) T2-4. The use of SLR varied from 18% to 77% in the six healthcare regions. Multiple adjuvant intravesical instillations were given to 420 patients (47%). SLR was associated with intravesical instillations, age younger than 74 years, discussion at multidisciplinary tumour conference, G3 tumour and treatment at high-volume hospitals. Patients undergoing SLR had a lower risk of dying from BC (hazard ratio 0.62, 95% confidence interval 0.45-0.84, pamp;lt;.0022). Five-year CSS rates were as follows, in patients with the indicated tumours at SLR (p=.001): 82% in those with T1, 90% in T0, 90% in Ta/Tis and 56% in T2-4. Conclusions: There are large geographical differences in the use of SLR in stage T1 BC in Sweden, which are presumably related to local treatment traditions. Patients treated with SLR have a high rate of residual tumour but lower age, which suggests that a selection bias affects CSS.

sted, utgiver, år, opplag, sider
TAYLOR & FRANCIS LTD , 2017. Vol. 51, nr 4, s. 301-307
Emneord [en]
Bladder cancer; cancer-specific survival; population-based; second-look resection; stage T1
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-139659DOI: 10.1080/21681805.2017.1303846ISI: 000405483400012PubMedID: 28398113OAI: oai:DiVA.org:liu-139659DiVA, id: diva2:1133666
Merknad

Funding Agencies|Swedish Cancer Society [CAN 2015/1155]; Lund University Medical Faculty [ALF 2014/354]

Tilgjengelig fra: 2017-08-16 Laget: 2017-08-16 Sist oppdatert: 2018-05-03

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Rosell, JohanJahnson, Staffan
Av organisasjonen
I samme tidsskrift
Scandinavian journal of urology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 149 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf